Analyst consensus rating
Capricor Therapeutics Analyst Rating: Buy
Direct answer
Capricor Therapeutics's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $27.00.
Forecast evidence checked October 17, 2026.
Get free Capricor Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.71
- Average price target
- $27.00
- High price target
- $54.00
- Low price target
- $7.00
- Low target gap
- +4.3%
- Target upside
- +302.4%
- High target gap
- +704.8%
- Target range width
- 700.4%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Capricor Therapeutics?
Capricor Therapeutics has a verified Buy consensus. The same dataset has an average price target of $27.00.
How far are Capricor Therapeutics's low and high targets from the recorded price?
The low target implies +4.3%, while the high target implies +704.8%.
How many analysts are included in Capricor Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Capricor Therapeutics's target upside or downside calculated?
The average target of $27.00 is divided by the recorded price of $6.71, then one is subtracted to produce +302.4%. This does not guarantee a future return.
When was Capricor Therapeutics's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.